Haploidentical NK Cells After Pemetrexed in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

5 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-11-09

Study Completion Date

2019-06-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This phase 1 trial investigate safety and maximum tolerated dose of natural killer (NK) cells derived from haploidentical family donors in patients with non-small cell lung cancer

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Maintenance Therapy With Autologous Cytokine-induced Killer Cells for Nonsquamous Non-small Cell Lung Cancer

NCT01481259

Non-small Cell Lung Cancer

UNKNOWN PHASE2/PHASE3

Clinical Efficacy and Safety of NK and NKT Cells Infusion in Patients With Non Small Cell Lung Cancer

NCT03198923

Non-small Cell Lung Cancer

UNKNOWN PHASE1

NK-cell Therapy Combined With PD-1 Antibody and Platinum-Based Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC

NCT07318636

Resectable Non-small Cell Lung Cancer

NOT_YET_RECRUITING PHASE1

A Study of Pemetrexed Plus Carboplatin Combined With Radiation in Patients With Inoperable Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC) (RT0801)

NCT00886678

Non-Small Cell Lung Cancer

UNKNOWN PHASE2

Clinical Study on Anti-tumor Effect Induced by Activated Primary Natural Killer（NK）Cells

NCT03634501

Lung Cancer Breast Cancer Colon Cancer +2 more

UNKNOWN PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Eligible patients receive pemetrexed 500 mg/m2 intravenously (Day 1). On Day 8, patients receive donor-derived NK cells via a central venous catheter.

The NK cell dose is as follows;

Level 1: 1.25 X 109 cells Level 2: 2.50 X 109 cells Level 3: 5.00 X 109 cells

Three patients each will be treated on each dose level.

Two weeks prior to donor NK cell administration to patients, HLA-haploidentical family member of the patients undergo leukapheresis after G-CSF injections to collect hematopoietic stem cells.

These donor cells are then taken to the laboratory, where they were differentiated into NK cells ex vivo over approximately over 2-week period.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-small Cell Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pemetrexed and donor NK cell infusion

Eligible patients with stage 4 non-small cell lung cancer receive NK cells derived from HLA-haploidentical family donors. One week prior to NK cell infusion, patients receive pemetrexed (500 mg/m2) intravenous infusion

Group Type EXPERIMENTAL

Pemetrexed and donor-derived NK cell infusion

Intervention Type BIOLOGICAL

Patients are administered with donor-derived NK cells one week after pemetrexed infusion

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pemetrexed and donor-derived NK cell infusion

Patients are administered with donor-derived NK cells one week after pemetrexed infusion

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with histologically confirmed non-small cell lung cancer stage 4 (by AJCC 7th)
* Age, 20 years of age or older
* ECOG performance status, 0-2
* Life expectancy ≥3 months
* Patients should have at least one measurable lesion according to RECIST Criteria v1.1
* Failure after primary systemic treatment with a regimen including platinum-containing agent (primary systemic treatment may be adjuvant chemotherapy or chemo-radiotherapy, given within 12 months)
* Adequate bone marrow function (Hb ≥9 g/dL; ANC ≥1,500/uL; and platelet count ≥75,000/uL)
* Adequate renal function (serum creatinine \<1 x ULN or CLcr ≥45 mL/min by Cockroft and Gault formula
* Adequate liver function (total bilirubin \<1.5 x ULN; AST and ALT \<3 x ULN; and ALP \<3 x ULN, unless there is bone metastases without evidence of liver disease)
* Patients should have a suitable HLA-haploidentical family member who is willing to donate hematopoietic stem cells
* Patients should sign informed consent voluntarily

Exclusion Criteria

* Patients who received anti-cancer chemotherapeutic or biological agents within 3 weeks. Patients who received anti-cancer treatment and did not recover from toxicities to grades 0-1 by NCI CTC AE ver 4.0 are not eligible as well.
* Patients with contraindication for any medication planned to be administered in the study
* Patients with significant fluid accumulation in third space (for example, pleural or pericardial effusion) that can not be controlled by drainage
* Active infectious process
* Inability to discontinue aspirin over 1.3 g daily or other NSAIDs. Patients cannot take aspirin or NSAIDs within 5 days of pemetrexed administration
* Major surgery within 4 weeks of study participation
* Palliative radiation therapy within 1 week of study participation
* Acute myocardial infarction within 6 months of study participation. History of uncontrolled arrhythmia, symptomatic angina, or symptomatic heart failure
* Past or current history of CNS metastasis (with exception of those patients who completed treatment of CNS metastasis and not received steroid treatment or whole brain radiotherapy within 2 weeks of screening visit or not received gamma knife treatment within 1 week of screening visit)
* History of malignancy (other than skin basal cell carcinoma, carcinoma in situ of uterine cervix, or thyroid cancer) within 5 years
* Pregnant or lactating women. Child-bearing women who are not willing to avoid pregnancy by contraceptives
* Man not agreeing to contraceptive measures such as condom or abstinence (It is recommended that contraceptive measures be used until 6 months after pemetrexed treatment)
* Other serious illness or medical condition

Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No